Rolapitant for the treatment of chemotherapy-induced nausea and vomiting

Expert Review of Anticancer Therapy

Volumn 15, Issue 10, 2015, Pages 1127-1133

  Navari, Rudolph M ^a,b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 hydroxytryptamine 3 receptor antagonists; antiemetics; aprepitant; chemotherapy induced nausea and vomiting; netupitant; rolapitant

Indexed keywords

APREPITANT; DEXAMETHASONE; FOSAPREPITANT; GRANISETRON; NETUPITANT; NETUPITANT PLUS PALONOSETRON; NEUROKININ 1 RECEPTOR AGONIST; PALONOSETRON; ROLAPITANT; SEROTONIN 3 ANTAGONIST; 8-((1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)METHYL)-8-PHENYL-1,7-DIAZASPIRO(4,5)DECAN-2-ONE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; SPIRO COMPOUND;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HEADACHE; HICCUP; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; NAUSEA; QUALITY OF LIFE; VOMITING;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; MORPHOLINES; NAUSEA; NEUROKININ-1 RECEPTOR ANTAGONISTS; PYRIDINES; QUALITY OF LIFE; SPIRO COMPOUNDS; VOMITING;

EID: 84942552223     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1088787     Document Type: Article

References (30)

1. Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: Time for more emphasis on nausea? Oncologist 2015; 20: 576-83
2. Navari RM. Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs 2013; 73: 249-62
3. Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 2014; 15: 2599-608
4. Aapro M, Carides A, Rapoport BL. Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. Oncologist 2015; 20: 450-8
5. Navari RM. Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 2015; 9: 155-61
6. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009; 28: 1-7
7. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): A randomized phase III trial. J Supp Oncol 2011; 9: 188-95
8. Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 2014; 22: 1143-51
9. Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. European J Pharm 2014; 722: 180-6
10. Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol 2012; 9: 20-6
11. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetic american society clinical oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-98
12. NCCN Clinical practice guidelines in oncology version 1. Antiemesis. national comprehensive cancer network (NCCN) [online]. Available from: www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf 2015
13. MASCC/ESMO antiemetic guidelines. Available from: www.mascc.org/antiemetic-guidelines. Updated 2013. [Last accessed 15 July 2015]
14. Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res International 2015; in press
15. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60: 533-46
16. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011; 29: 1495-501
17. Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist netupitant. Peptides 2012; 37: 86-97
18. Rossi G, Tilkola SO, Rudengren C, et al. A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects. J Clin Oncol 2012; 30; Abstract 9054
19. Spinelli T, Calcagneli S, Giuliano C. Netupitant PET Imaging and ADME studies in humans. J Clin Pharm 2014; 54: 97-108
20. National cancer institute drug dictionary. Available from: www.cancer.gov/drug dictionary. [Last accessed 15 July 2015]
21. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 01340-6
22. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-33
23. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25: 1333-9
24. Schwartzberg L, Aapro M, Hesketh PJ, et al. Do NK-1 receptor antagonists contribute to nausea control? Evaluation of the novel NEPA fixed-dose combination of NK-1 receptor antagonist plus a 5-HT3 receptor antagonist from pivotal trials. Support Care Cancer 2014; 22: 107; Abstract 161
25. Duffy RA, Morgan C, Naylor R, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK-1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav 2012; 102: 95-100
26. Poma A, Christensen J, Pertikis H, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer 2013; 21: S154; Abstract 441
27. Poma A, Christensen J, Davis J, et al. Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol 2014; 32; Abstract e20690
28. Rapoport B, Chua D, Poma A, et al. Study of rolapitant, a novel, long acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support. Care Cancer 2015
29. Schwartzberg L, Modiana M, Rapoport B, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomized phase 3 trial. Lancet Oncol 2015; in press
30. Rapoport B, Chasen M, Gridelli C, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomized phase 3 trials. Lancet Oncol 2015; in press